Search

The interaction of von Willebrand factor with platelet glycoprotein Ib: pathological implications and clinical manifestations

The EHA Specialized Working Group (SWG) on Thrombocytopenias and Platelet Function Disorders and the EHA-SWG on Bleeding and Thrombosis are pleased to collaborate on a recent free webinar: "The interaction of von Willebrand factor with platelet glycoprotein Ib: pathological implications and clinical…

Read more

Research must provide ‘more good news on outcomes’ while patients need simple and effective information

On behalf of EHA, professor Giovanni Martinelli and professor Theo de Witte spoke of their cutting edge research and the next steps in personalized medicine research in hematology.

Read more

Session information—March 25, 2025

Topic'Infections caused by multidrug-resistant (MDR) pathogens in hematological patients.

Read more

FP9 recommendations BioMed Alliance

With preparations under way for the EU’s next Framework Programme for Research and Innovation (FP9), the BioMed Alliance has called for more robust EU support for health research.

Read more

EHA-EBMT 2nd European CAR T Cell Meeting

Dates:             January 30 – February 1, 2020
Location:        Sitges (Barcelona), Spain
Chairs:            H Einsele, C Chabannon

The 2nd edition of this meeting is jointly organized by the European Hematology Association (EHA) and the European Society for Blood and Marrow Transplantation (EBMT).…

Read more

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).

Read more